Eva E. Medvedova

Hematology

3303 S Bond Ave
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

124Iodine Evuzamitide Positron Emission Tomography in Patients with Established or Suspected Cardiac Amyloidosis.

124Iodine Evuzamitide Positron Emission Tomography in Patients with Established or Suspected Cardiac Amyloidosis.

Journal: JACC. Cardiovascular imaging

Published: May 15, 2026

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Journal: Blood advances

Published: February 18, 2026

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Journal: The New England journal of medicine

Published: December 08, 2025

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

Journal: Cancer

Published: November 22, 2025

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Journal: British journal of haematology

Published: November 14, 2025

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Journal: Blood

Published: October 07, 2025

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Journal: Blood

Published: October 07, 2025

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Journal: The New England journal of medicine

Published: December 09, 2024

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.

Journal: Blood

Published: November 13, 2024

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.

Journal: Blood cancer journal

Published: November 05, 2024

Acute deep vein thrombosis with concurrent new diagnosis of AL-amyloid-induced factor X deficiency.

Acute deep vein thrombosis with concurrent new diagnosis of AL-amyloid-induced factor X deficiency.

Journal: BMJ case reports

Published: June 05, 2024

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Journal: Blood cancer journal

Published: September 22, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026